MENU
+Compare
CRDF
Stock ticker: NASDAQ
AS OF
Jun 6, 04:59 PM (EDT)
Price
$3.88
Change
+$0.26 (+7.18%)
Capitalization
240.49M

CRDF Cardiff Oncology Forecast, Technical & Fundamental Analysis

Cardiff Oncology Inc is a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers with the greatest unmet medical need... Show more

CRDF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I.Advisor
a Summary for CRDF with price predictions
Jun 05, 2025

CRDF in upward trend: 10-day moving average crossed above 50-day moving average on May 29, 2025

The 10-day moving average for CRDF crossed bullishly above the 50-day moving average on May 29, 2025. This indicates that the trend has shifted higher and could be considered a buy signal. In of 12 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on May 19, 2025. You may want to consider a long position or call options on CRDF as a result. In of 91 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

CRDF moved above its 50-day moving average on May 23, 2025 date and that indicates a change from a downward trend to an upward trend.

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where CRDF advanced for three days, in of 239 cases, the price rose further within the following month. The odds of a continued upward trend are .

The Aroon Indicator entered an Uptrend today. In of 177 cases where CRDF Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Bearish Trend Analysis

The RSI Indicator has been in the overbought zone for 2 days. Expect a price pull-back in the near future.

The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 7 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

The 50-day moving average for CRDF moved below the 200-day moving average on May 14, 2025. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where CRDF declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

CRDF broke above its upper Bollinger Band on May 29, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. CRDF’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.393) is normal, around the industry mean (16.332). P/E Ratio (0.000) is within average values for comparable stocks, (59.787). CRDF's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (2.227). Dividend Yield (0.000) settles around the average of (0.040) among similar stocks. P/S Ratio (322.581) is also within normal values, averaging (263.647).

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CRDF’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock better than average.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

View a ticker or compare two or three
CRDF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I. Advisor
published Earnings

CRDF is expected to report earnings to fall 1.45% to -19 cents per share on July 31

Cardiff Oncology CRDF Stock Earnings Reports
Q2'25
Est.
$-0.20
Q1'25
Missed
by $0.01
Q4'24
Beat
by $0.03
Q3'24
Beat
by $0.02
Q2'24
Missed
by $0.01
The last earnings report on May 08 showed earnings per share of -20 cents, missing the estimate of -18 cents. With 626.86K shares outstanding, the current market capitalization sits at 240.49M.
A.I. Advisor
published General Information

General Information

a cancer medicine oncology therapeutics company, which engages in the development of drugs that target cell division (mitosis), for the treatment of various cancers including leukemia, lymphomas, and solid tumors

Industry Biotechnology

Profile
Fundamentals
Details
Industry
N/A
Address
11055 Flintkote Avenue
Phone
+1 858 952-7570
Employees
32
Web
https://www.cardiffoncology.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
OEPIX58.24N/A
N/A
Oil Equipment&Svcs UltraSector Pro Inv
PCHSX30.44N/A
N/A
Putnam Global Health Care C
HGORX57.68N/A
N/A
Hartford Growth Opportunities R3
SDVRX24.39N/A
N/A
PGIM Quant Solutions Mid-Cap Val R
FNIDX13.76N/A
N/A
Fidelity Intl Sustainability Idx

CRDF and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, CRDF has been loosely correlated with CMRX. These tickers have moved in lockstep 45% of the time. This A.I.-generated data suggests there is some statistical probability that if CRDF jumps, then CMRX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CRDF
1D Price
Change %
CRDF100%
-0.14%
CMRX - CRDF
45%
Loosely correlated
N/A
MRVI - CRDF
43%
Loosely correlated
-1.81%
ABSI - CRDF
42%
Loosely correlated
-0.35%
NAMS - CRDF
40%
Loosely correlated
+0.67%
BEAM - CRDF
40%
Loosely correlated
-0.87%
More